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Abstract 
Background: Previous studies suggest that certain transition metal complexes, such as cisplatin, are efficacious for 
treating various cancer types, including ovarian, lung, and breast.
Methods: In order to further evaluate ruthenium (Ru) complexes as potential anti‑cancer agents, we synthesized and 
evaluated Ru‑arene complexes. Two complexes with the general formula [Ru (η6‑p‑cym) (N–N) Cl]+ were tested for 
their abilities to inhibit cancer cells.
Results: The complex with o‑phenylenediamine as the N–N ligand (o‑PDA) significantly inhibited growth of breast 
(MDA‑MB‑231, MCF‑7, SKBR‑3, and SUM149), lymphoma (Raji), melanoma (Bowes), and osteosarcoma (HT1080); how‑
ever, the complex with o‑benzoquinonediimine (o‑BQDI) was ineffective except for SUM149. In contrast, o‑PDA failed 
to inhibit growth of human breast epithelial cells, MCF‑10A. Treatment of MDA‑MBA‑231 cells with o‑PDA resulted in a 
significant reduction of productions of PDGF‑AA, GM‑CSF, and VEGF‑A proteins at the transcriptional levels. Finally, we 
demonstrated that o‑PDA synergistically inhibited MDA‑MB‑231 cell growth with cyclophosphamide but not doxoru‑
bicin or paclitaxel.
Conclusion: These results suggest that Ru‑arene complexes are promising anti‑cancer drugs that inhibit progression 
and metastasis by blocking multiple processes for breast and other types of cancer.
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Background
According to the latest issue of Cancer Facts and Fig-
ures (2015), more than 230,000 women will be diagnosed 
with invasive breast cancer in the USA and nearly 40,000 
patients will die, ranking breast cancer second among 
cancer related deaths for women. When breast cancer 
cells express hormone receptors, including progesterone, 
estrogen, or Her2/neu receptors, there are several effec-
tive treatments targeting these receptors. Triple negative 
(TN) breast cancer, which comprises 15–20  % of breast 
cancer cells, lack these receptors and can aggressively 
invade and metastasize to distant organs. One current 
requirement for treating TN breast cancer is to develop 
therapeutic regimens that will maximize complete 
pathologic response rates to improve patient progno-
sis. Thus, the immediate requirements for treating TN 
breast cancer are to establish precise target therapies for 
patients by developing novel complexes that inhibit TN 
breast cancer invasion and metastasis in order to enhance 
patient response for improving patient outcomes.
There is substantial evidence demonstrating that 
metal-based reagents are promising candidates for can-
cer therapies. For example, complexes possessing plati-
num (Pt), such as cisplatin, carboplatin, and oxaliplatin, 
have been used to treat various cancer types such ovary, 
stomach, and colon [1, 2]. One of the mechanisms 
explaining how Pt complexes inhibit cancer cell growth 
is that they cause interstrand and intrastrand cross-link-
ing of DNA, thereby inhibiting DNA repair or replica-
tion [3]. However, previous studies demonstrated that Pt 
complexes have severe side effects and generate resistant 
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in clinical practice [4]. Nevertheless, metal based rea-
gents are promising anti-cancer drugs due to their ease 
of chemical modification and wide-spectrum of effective-
ness against various origins of cancer.
Ru complexes are potent growth inhibitors for vari-
ous cancer cells such as melanoma, ovarian, and breast 
[5–10]. Ru complexes have been proposed as an alterna-
tive to Pt complexes for development of novel anti-cancer 
drugs. Indeed, several Ru complexes are under phase I 
or II clinical trials [11–13]. Based on the structure-activ-
ity relationship studies, Ru complexes may function to 
inhibit tumor cells through mechanisms similar to that of 
cisplatin [14]. Some ruthenium (III) complexes (NAMI-
A, KP1019 and KP1330) are in Phase II clinical trials [15]. 
In addition other organometallic ruthenium (II) arene 
complexes, RM175 and RAPTA complexes, have also 
shown promise [16, 17]. The nature of the ligands bound 
to the metal is important to the activity of the drug. In 
this study, we demonstrated that the Ru-arene complex 
[Ru(η6-p-cymene)(o-phenylendiamine)Cl]+ (o-PDA) is a 
potent anti-cancer reagent against breast cancer, osteo-
sarcoma, lymphoma, and melanoma cells, while it did 
not affect cell growth of human epithelial cells, MCF10A. 
Using MDA-MB-231 cells, we demonstrated that o-PDA 
inhibited production of soluble growth factors such as 
VEGF-A, PDGF-AA, and GM-CSF at the transcrip-
tional levels. Moreover, o-PDA and cyclophosphamide 
synergistically inhibited breast cancer cell growth. Thus, 
we provided information regarding the mechanisms of 
Ru-arene complex o-PDA to inhibit cancer cell growth, 
which supports synthesizing and testing additional Ru-
arene complexes as novel anti-cancer agents.
Methods
Cell lines
Cell lines used in this study (MCF-10A, HCC38, SK-Br3, 
MCF-7, MDA-MB-231, HCC1806, Raji, Bowes, HT1080, 
and dermal fibroblasts) were purchased from ATCC. 
SUM149 cells were obtained from Dr. Soldano Ferrone 
(Massachusetts General Hospital, Boston, MA USA). 
MCF-10A cells were maintained in DMEM/F12 contain-
ing 5 % horse serum, 20 ng/ml EGF, 0.5 μg/ml hydrocor-
tisone, 100 ng/ml cholera toxin, 10 μg/ml insulin, and 1 % 
penicillin/streptomycin. All other cell lines were cultured 
in RPMI640 containing 10 % FBS. Cells were cultured no 
more than 30 days after thaw in order to minimize phe-
notypic drift.
Reagents
WST-1, doxorubicin, paclitaxel, and cyclophosphamide 
were purchased from CalBiochem (San Diego, CA, USA). 
Other reagents were purchased from Sigma-Aldrich (St. 
Louis, MO, USA) unless otherwise mentioned.
Syntheses of Ru‑complexes
The following reagents were obtained from Sigma-
Aldrich: [(p-cymene)RuCl2]2 (p-cym), o-phenylenedi-
amine (o-pda), and ammonium hexafluorophosphate 
(NH4PF6). Solvents were reagent grade. Benzene and die-
thyl ether were used as received. Methanol was distilled 
over iodine and magnesium.
[(p‑cym)Ru(o‑pda)Cl]PF6 (o‑PDA) [6]
In a side-arm flask charged with nitrogen, [(η6-p-cym) 
RuCl2]2 (50.8 mg, 0.081 mmol) was suspended in 20 ml 
of freshly distilled methanol with stirring. After 5  min, 
o-pda (20.3 mg, 0.188 mmol) was added whereupon the 
deep orange solution immediately turned yellow. The 
solution was stirred at room temperature under nitrogen 
flow. After 30  min the solution was warmed in a water 
bath and the volume reduced to ½ under a steady flow of 
nitrogen; solid NH4PF6 (0.1205 g, 0.713 mmol) was added 
and the flask shaken to induce precipitation. The pale 
yellow precipitate was filtered and washed with diethyl 
ether and air-dried.
[(p‑cym)Ru(o‑bqdi)Cl]PF6 (o‑BQDI) [6]
In a typical preparation [(η6-p-cym)RuCl2]2 (49.8  mg, 
0.0813  mmol) and o-pda (21.0  mg, 0.184  mmol) were 
combined in 30  ml of freshly distilled methanol in a 
125 ml Erlenmeyer flask and stirred in air at room tem-
perature. The solution rapidly changed color from deep 
orange to dark purple. After 30  min, the volume was 
reduced to one-third by rotary evaporation and solid 
NH4PF6 (0.0608 g, 0.360 mmol) was added. Deep purple 
crystals formed after sitting in air overnight. The solid 
was recovered by vacuum filtration, rinsed with metha-
nol and diethyl ether, and air-dried.
Growth factor protein array study
MDA-MB-231 cells were seeded in 6-well plates in 
RPMI1640 containing 10  % FBS. Medium was replaced 
with serum-free RPMI1640 12  h before treatment with 
Ru complexes to minimize the residual effects on growth 
factor production by FBS-derived soluble factors. Cells 
were washed 4 times with serum-free RPMI1640 and 
incubated for 48  h with o-PDA and o-BQDI at a final 
concentration of 130  μM. Serum-free conditioned 
medium was collected and centrifuged for 3  min at 
13.2  ×  1000  rpm at room temperature to remove cell 
debris. The supernatant was immediately subjected to 
Human Growth Factor Antibody Array (Cat # AAH-
GF-1, RayBiotech, Norcross, GA, USA) according to 
the manufacturer’s protocol. Briefly, antibody array was 
blocked for 30  min at room temperature with shaking 
and then incubated with 1  ml of conditioned medium 
at 4  °C overnight. The membranes were washed and 
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incubated with biotinylated antibody cocktail at 4  °C 
overnight under constant shaking. The membranes were 
washed and the HRP-conjugated streptavidin was pre-
pared and incubated with the membranes at 4  °C over-
night under constant shaking. Finally, the membranes 
were washed and signals were detected using the detec-
tion reagents provided in the kit.
Quantitative RT‑PCR (qRT‑PCR)
MDA-MB-231 cells were seeded in 10  mm tissue cul-
ture dishes. Cells were allowed to grow to ~80 % conflu-
ency before treatment with either o-PDA or o-BQDI at 
a final concentration of 130  μM. Cells were incubated 
at 37  °C under 5  % CO2 for 48  h. Cells were harvested 
from both medium and dishes by brief trypsinization. 
Total RNA was isolated by RNeasy Mini Kit protocol 
(QIAGEN, Redwood City, CA, USA). RNA was homog-
enized using QIAshredder (QIAGEN, Redwood City, 
CA, USA) and the first strand DNA was synthesized with 
High Capacity cDNA Reverse Transcription Kit accord-
ing to manufacture protocol (Applied Biosystems, Foster 
City, CA, USA). PCR amplification was performed using 
TaqMan Universal PCR Master Mix (Applied Biosys-
tems, Foster City, CA, USA). The TaqMan gene expres-
sion assays (Applied Biosystems, Foster City, CA, USA) 
used are as follows: PDGFA (Hs00964426_m1), GM-CSF 
(Hs00929873_m1), VEGF-A (Hs00900055_m1), and 
GAPDH (Hs02758991_g1) as reference gene. The reac-
tions were first kept for 2  min at 50  °C followed by for 
10 min at 95  °C. The cycling condition was 40 cycles of 
15 s at 95 °C and 1 min at 60 °C. Quantification of gene 
expression was determined by Comparative Ct using ViiA 
7 Real-Time PCR System (Applied Biosystems, Foster 
City, CA, USA).
Statistical analysis
Two-tailed (paired) Student’s t test was used to calculate 
statistical significance between control and experimental 
groups. A p value of less than 0.001 is considered as sig-
nificant difference between the groups.
Growth assays
Cells were harvested with brief treatment with trypsin–
EDTA and resuspended in RPMI-1640 containing 10  % 
FBS at a concentration of 1–2  ×  105 cells/ml. Cells 
(100  μl/well) were plated into 96-well plates and filled 
with an additional 100  μl/well of RPMI1640-10  % FBS. 
Cells were incubated at 37  °C under 5  % CO2 for 24  h, 
washed briefly, and incubated in the presence or absence 
of reagents at indicated concentrations for an additional 
48  h. WST-1 (10  μl/well) was added to each well at the 
last 2 h of incubation and the absorbance at 450 nm was 
measured. As a control, the Ru complexes or anti-cancer 
reagents (i.e. puromycin) were incubated without cells for 
48 h and incubated with WST-1 in order to compensate 
for the absorbance by these complexes. Cell growth was 
determined by measuring OD at 450  nm. Experiments 
were repeated at least three times with quadruplicate. 
Results were demonstrated as a mean % growth inhibi-
tion compared to control  ±  standard deviation (SD). 
EC50 was calculated according to the methods reported 
previously [18].
Results
Structural features of Ru‑arene complexes used in this 
study
The complexes used in this study are shown in Fig.  1. 
They were prepared according to previously published 
procedures and characterized by UV–visible electronic 
absorption spectroscopy and 1H and 13C NMR. The 
spectral properties of the complexes agree with the val-
ues from the literature [6, 19]. The same starting mate-
rials were used to prepare both complexes. The o-PDA 
complex was prepared with freshly distilled methanol 
under nitrogen. When the procedure is carried out in 
air, ligand-based oxidation produces the diimine com-
plex (o-BQDI). Chloride occupies the sixth binding site 
and the complexes are isolated as PF6− salts. The com-
plexes undergo hydrolysis in aqueous solution with water 
replacing the chloro ligand.
Ruthenium arene complexes of the general formula 
[Ru(η6-arene)(N–N)Cl]+, have three key structural fea-
tures (Fig.  1): the arene ligand para-cymene (p-cym), a 
bidentate ligand with nitrogen as the donor atoms (N–N) 
and chloride as the other ligand. In this study, the N–N 
ligands are the aromatic diamine, ortho-phenylenedi-
amine (o-PDA) or the oxidized form, ortho-benzoqui-
nonediimine (o-BQDI). Binding studies of [(η6-arene)
Ru(diamine)X]+ complexes show preferential binding 
between the metal and N7 of guanine bases on DNA [9]. 
The interaction is further stabilized through hydrogen 
bonding between the N–H of the amine and the C6O of 
the guanine [20, 21].
Growth inhibition by Ru‑arene complexes against various 
cancer cells
We first tested the growth inhibitory activity of the Ru-
arene complexes for various cancer cells. Cells were incu-
bated with various concentrations (0–260 μM) of o-PDA 
or o-BQDI for 48 h and then the growth was measured 
by colorimetric assays using WST-1. We tested human 
cells including breast cancer (HCC38, HCC1806, SKBr-
3, MCF-7, and SUM149), B-cell lymphoma (Raji), osteo-
sarcoma (HT1080), and melanoma (Bowes) (Additional 
file  1: Figure S1). Among the cell lines tested, MCF-7 
(breast cancer, luminal A) and SK-Br-3 (breast cancer, 
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Her2+) were most sensitive cells at EC50 of 50  μM of 
o-PDA (Table  1; Additional file  1: Figure S1). O-PDA 
inhibited growth of SUM149 (breast cancer, triple-neg-
ative), HT1080 (osteosarcoma), Raji (lymphoma), and 
Bowes (melanoma) at EC50 of 110 to 150  μM (Table  1; 
Additional file  1: Figure S1). Interestingly, growth of 
two breast cancer cell lines of triple-negative phenotype 
HCC38 and HCC1806 were not inhibited at the concen-
trations of o-PDA used in this study (Table 1; Additional 
file  1: Figure S1). On the other hand, o-BQDI did not 
show any growth inhibitory activity for cells except for 
SUM149 (Table  1; Additional file  1: Figure S1). Growth 
of SUM149 cells were inhibited at 40  % at the highest 
concentration (Additional file  1: Figure S1). The rela-
tively higher EC50 obtained in this study compared other 
studies maybe due to the assay systems as direct count-
ing cells and colorimetric assays using WST-1 [19]. Thus, 
these results suggest that o-PDA inhibited various cancer 
cell growth on a cell-type specific manner.
In order to evaluate Ru-Arene complexes against met-
astatic breast cancer cells, we used MDA-MB-231 as a 
model system (Additional file 2: Figure S2). Cisplatin has 
been demonstrated as a potent anti-cancer agent against 
breast cancers [22]. o-PDA but not o-BQDI significantly 
inhibited growth of MDA-MB-231 cells was inhibited by 
o-PDA at EC50 = 83 μM (Table 2; Additional file 2: Fig-
ure S2). As previously reported [22], growth of MDA-
MB-231 cells was inhibited in a concentration-dependent 
manner by cisplatin (IC50 = 53 μM) (Table 2; Additional 
file  2: Figure S2). MCF-10A cells are a spontaneously 
immortalized human epithelial cell line and show nor-
mal mammary epithelial cell morphology [23]. MCF-10A 
cells are used as a normal control in breast cancer studies 
[23]. When MCF-10A cells were incubated in the pres-
ence of Ru-Arene complexes, neither complex inhibited 
growth of cells at the concentrations tested (Table  2; 
Additional file  2: Figure S2), while growth was signifi-
cantly inhibited even at 2.8  μM of cisplatin (Table  2; 
Additional file  1: Figure S1). These results suggest that 
o-PDA would be a potential therapeutic agent against 
metastatic breast cancer cells with minimal effect against 
breast epithelial cells.
Inhibition of growth factor productions by o‑PDA
In order to ask whether o-PDA could have potential 
effects on breast cancer cells which could confer pro-
gression and metastasis, we analyzed the production of 
soluble factors from MDA-MB-231 cells, Cells were incu-
bated with 130  μM of o-PDA or o-BQDI for 48  h and 
the conditioned medium was subjected to growth factor 
Fig. 1 Structures of Ru‑complexes used in this study. Structure of ruthenium complexes used in this study where N–N is either 1,2‑phenylenediam‑
mine (o‑pda) or 1,2‑benzoquinonediimine (o‑bqdi)
Table 1 Effects of  RU-complexes on  growth of  various 
human cancer cells
TN triple-negative, LA luminal A
a Cells (2 × 105 cells/well) were treated serially diluted o-PDA or o-BQDI for 48 h. 
Cell growth was evaluated by colorimetric assays using WST-1 as an indicator. 
Experiments were repeated three times
b EC50 was calculated from three independent experiments. Standard error was 
less than 5 % of mean
Cell linea EC50(µM)b
o‑PDA o‑BQDI
HCC38 (breast ca. TN) >260 >260
HCC1806 (breast ca. TN) >260 >260
MCF‑7 (breast ca. LA) 50 >260
SUM149 (breast ca. TN) 150 >260
HT1080 (osteosarcoma) 130 >260
Raji (lymphoma) 160 >260
Bowes (melanoma) 110 >260
SK‑Br‑3 (breast ca. Her2+) 50 >260
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protein array. The production of PDGF-AA, VEGF-A, 
and GM-CSF was markedly reduced when cells were 
incubated in the presence of o-PDA but not with o-BQDI 
(Fig.  2a). In order to test whether the inhibition of the 
proteins of growth factors would be the result of tran-
scriptional regulation, we performed quantitative RT-
PCR (qRT-PCR) analyses to estimate copy numbers of 
these growth factors from MDA-MB-231 cells treated 
with o-PDA, and o-BQDI. These results demonstrated 
that treatment with o-PDA markedly reduced copy 
numbers of transcripts of PDGF-AA, VEGF-A, and GM-
CSF compared to the control and o-BQDI-treated cells 
(Fig. 2b), suggesting that o-PDA reduces the production 
of specific growth factors in MDA-MB-231 cells at the 
transcriptional levels.
Growth inhibition of breast cancer cells by combination 
of o‑PDA and chemotherapeutic agents
In order to test whether o-PDA would enhance the cyto-
toxic activity of chemotherapeutic agents, MDA-MB-231 
cells were incubated in the presence of suboptimal con-
centrations of o-PDA (32  μM) and cyclophosphamide 
(10  mM) for various time intervals from 5  min to 48  h 
(Fig. 3). Cyclophosphamide inhibited MDA-MB-231 cell 
growth at the same concentration range reported previ-
ously [24]. When cells were incubated up to 48 h in the 
presence of both reagents, a significant growth inhibition 
was observed in a time-dependent manner compared to 
single treatments. This synergistic growth inhibition was 
observed when cells were incubated for as little as 90 min 
(Fig.  3). These results suggest that o-PDA and cyclo-
phosphamide synergistically inhibited breast cancer cell 
growth in a time-dependent manner.
Table 2 Effects of  Ru-complexes on  growth of  MDA-
MB-231 and MCF-10A cells
a Cells (2 × 10 cells/well) were treated serially diluted o-PDA, o-BQDI or cisplatin 
for 48 h. Cell growth was evaluated by colorimetric assays using WST-1 as an 
indicator
b EC50 was calculated from three independent experiments. Standard error was 
less than 5 % of mean
Cell linea EC50(µM)b
o‑PDA o‑BQDI Cisplatin
MDA‑MB‑231 83 >260 53
MCF10A >260 >260 2.8
Fig. 2 Inhibition of growth factor production from MDA_MB‑231 cells treated with o‑PDA. MDA‑MB‑231 cells were incubated in the presence of o‑
PDA or o‑BQDI at a concentration of 130 μM for 48 h in serum‑free RPMI1640. a Conditioned medium was harvested, centrifuged, and subjected to 
Human Growth Factor Array. b Cells were harvested and total RNA was purified, transcribed, and then subjected to RT‑PCR reactions using specific 
primer sets for GM‑CSF, VEGF‑A, and PDGF‑AA
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On the other hand, when cells were incubated in the 
presence of o-PDA and doxorubicin or paclitaxel, no 
significant synergistic growth inhibition was observed 
(Fig.  4). These results suggest specific mechanisms of 
growth inhibition of o-PDA and cyclophosphamide.
Discussion
It has been suggested that several unique features of 
ruthenium (Ru)-arene complexes would be beneficial for 
developing anti-cancer drugs. One is the ease of chemi-
cal structure modification by substituting different arene 
ligands and the bidentate O- and N- donor ligands. 
Another is the design complexes that will bind to cell 
surface receptors such as transferrin receptor (CD71) or 
integrins [25, 26]. In this study, we demonstrated that o-
PDA significantly inhibited not only breast cancer cells 
but also other cancer cell types including osteosarcoma, 
melanoma, and lymphoma. Additionally, it did not affect 
normal epithelial (MCF-10A) cell growth. Using MDA-
MB-231 cells as a model system, we demonstrated that 
o-PDA inhibited the production of critical growth fac-
tors such as PDGF-AA, GM-CSF, and VEGF-A at the 
transcriptional levels. Importantly, combining subop-
timal concentrations of o-PDA and cyclophosphamide 
enhanced cytocidal activity in MDA-MB-231 cells. 
These results suggest that Ru-Arene complexes are 
potential anti-cancer reagents per se in monotherapy 
as well as in combination with neoadjuvants such as 
cyclophosphamide.
Sadler and co-workers observed cell-type specific 
growth inhibition by o-PDA [8, 27]. In this study, we 
explored various cell lines for their sensitivities against 
this complex. Growth of melanoma, lymphoma, and oste-
osarcoma was significantly inhibited by o-PDA. Among 
breast cancer cells, growth of Her2+ (SK-Br-3), luminal A 
(MCF-7), and triple-negative (MDA-MB-231) was inhib-
ited in the presence of o-PDA in a concentration-depend-
ent manner. However, other triple-negative breast cancer 
cells, HCC38 and HCC1806, were resistant to this com-
plex. There is insufficient information to understand the 
cell type-specific growth inhibition by o-PDA at present. 
Extensive structure-activity studies have shown that all 
three components (arene ligand, N–N donor ligand and 
chloride) are important to cytotoxicity of Ru complexes 
Fig. 3 Inhibition of cell growth by o‑PDA and cyclophosphamide. MDA‑MB‑231 cells (1.25 × 104 cells/well) were incubated over various time peri‑
ods in the presence of cyclophosphamide alone (10 mM) (), o‑PDA alone (32 μΜ) (), or the combination of the two reagents () for up to 48 h. Cells 
were incubated with Puromycin (25 mM) for 48 h (). Cell growth was evaluated by colorimetric assays using WST‑ as an indicator. Experiments were 
repeated three times. Results were demonstrated as a mean ± SD of OD450. *p < 0.001 (calculated by Student’s two‑tailed t test)
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[8, 9, 27–29]. More specifically, cytotoxic behavior is not 
observed (high IC50) in [(η6-arene)Ru(N–N)Cl]+ com-
plexes which cannot form NH-C6O hydrogen bonds 
[8]. Computational studies of the 9-ethylguanine adduct 
of o-PDA shows Ru binding to N7 with hydrogen bond-
ing between C6O of the guanine and the coordinated 
o-PDA. The planar structure of the oxidized o-bqdi 
ligand imparts rigidity resulting in a greater distance 
between the NH protons and a much weaker hydrogen 
bond to C6O [27]. Adhireksan et  al. [30] performed a 
very detailed structure-activity relationship study of two 
Ru-arene complexes on cell growth inhibition and dem-
onstrated that a cytotoxic Ru-arene complex targets the 
DNA of chromatin, while a non-cytotoxic complex forms 
adducts within the histone proteins. This is an attrac-
tive hypothesis which may explain the cell-type specific 
growth inhibition by Ru-arene complexes. While cispl-
atin significantly inhibited normal human epithelial cells, 
MCF-10A, this cell line was resistant against the treat-
ment with o-PDA. These results suggest that Ru-Arene 
complexes such as o-PDA would be attractive anti-cancer 
reagents with minimal growth inhibitory activity against 
breast epithelial cells.
Previous studies demonstrated that soluble factors 
produced from malignant tumor cells would alter 
tumor/tissue microenvironments favoring tumor 
growth and invasion into surrounding tissues. For 
example, the production of PDGF-A is significantly 
associated with lymph node metastasis of breast can-
cer cells [31]. Furthermore, PDGF-A and its receptor 
PDGF-α expressions on the same breast cancer cells 
suggest that PDGF-A/PDGF-α loop would function 
Fig. 4 Inhibition of cell growth by the combination of o‑PDA with other cytotoxic agents. MDA‑MB‑231 cells (1.25 × 104 cells/well) were incubated 
for 2 days in the presence of Doxorubicin (DOX, 5 μM) (a), Paclitaxel (PT 5 μM) (b) or cyclophosphamide (CY 10 mM) (c) with or without o‑PDA (32 
μΜ). Puromycin (25 mM) was used as a positive control. Cell growth was evaluated by colorimetric assays using WST‑1 as an indicator. Experiments 
were repeated three times. Results were demonstrated as a mean ± SD of OD450. *p < 0.001 (calculated by Student’s two‑tailed t test)
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as an autocrine growth mechanism [32]. Importantly, 
previous studies demonstrated that neovasculariza-
tion surrounding tumor mass is a critical process for 
facilitating progression and metastasis. Indeed, it 
was reported that the expression of VEGF-A is asso-
ciated with shorter survival times with triple nega-
tive breast cancer patients [33]. These results suggest 
that targeting VEGF-A may be an alternative way to 
improve outcomes in patients who are diagnosed with 
triple-negative phenotype. Breast cancer cells tend 
to metastasize to bone and modulate the biological 
functions of bone cells. Utilizing MDA-MB-231 cells, 
Mendoza-Villanueva et al. [34] reported that GM-CSF 
and IL-11 play a key role in inducing differentiation 
of osteoblasts. Thus, it is anticipated that inhibition of 
GM-CSF from breast cancer cells may have an impact 
on the bone cell functions such as osteoblasts at the 
metastasized lesion. In this study, we demonstrated 
that inhibiting the production of VEGF-A, PDGF-AA, 
and GM-CSF by treatment with o-PDA would lead to 
an efficient blockade of tumor growth and osteoblasts 
functions at bone.
The regulation of VEGF-A protein production is 
mediated by multiple pathways. For example, it is 
reported that endoplasmic reticulum ER-associated 
degradation pathways are key processes for degrad-
ing unassembled subunits of multimeric proteins [35]. 
Vesicles containing VEGF-A molecules are trans-
ported through the ER-Golgi apparatus, in which 
they become encapsulated in vesicles. These vesicles 
may be subjected to degradation through ubiquitina-
tion followed by degradation of proteasomes, thereby 
degrading VEGF-A in the cytoplasm prior to exocy-
tosis [36]. Thus, one explanation for the discrepancy 
of the production of VEGF-A protein and mRNA in 
MDA-MB-231 cells treated with or without o-BQDI 
is the possibility that the production of VEGF-A pro-
tein could be regulated on the post-translational level 
including ubiquitination-proteasome systems for pro-
ducing appropriate amounts of VEGF-A, which is an 
analogy for regulation of transcription factors [37]. As 
an alternative explanation, it might be possible that 
o-BQDI would prevent production of VEGF-A from 
cells by attenuating cytoplasmic translocation and/
or bursting of VEGF-A-containing vesicles by altering 
intracellular pH [38]. Indeed, previous studies demon-
strated that a ruthenium compound changed intracel-
lular pH in neuron cells [39]. Therefore, it would be 
important to characterize mechanisms of regulation of 
intracellular environment by anti-cancer drugs (i.e. Pt 
and Ru compounds) for developing therapeutic strate-
gies for cancer patients.
Recent studies suggest that multiple modulating strat-
egies in combination with chemotherapeutic reagents 
would be promising approaches for improved treatment 
of breast cancer [40]. In order to maximize therapeutic 
efficacy while decreasing the side effects of the reagents, 
there is a need to develop molecules that synergisti-
cally inhibit cancer cell growth with chemotherapeutic 
reagents. We demonstrated that o-PDA synergistically 
inhibited MDA-MB-231 cells with cyclophosphamide. 
Clinically, cyclophosphamide has been used as an effec-
tive chemotherapeutic agent for breast cancer patients 
[41]. Cyclophosphamide is a alkylating reagent that 
attaches to the N7 of guanine and forms interstrand and 
intrastrand DNA crosslinks [42]. As discussed above, o-
PDA will bind to N7 of guanine through Ru and the NH 
of the o-PDA ligand forms hydrogen bonds with the car-
bonyl oxygen of carbon 6, thereby inducing premature 
termination of RNA synthesis [20, 21, 28, 43]. Thus, it 
is postulated that targeting N7 of guanine would be one 
of the mechanisms of the observed synergistic effect by 
o-PDA and cyclophosphamide to inhibit MDA-MB-231 
cell growth. Treatment of mice bearing melanoma 
with cyclophosphamide induces immunosuppression 
in an inflammation-dependent manner and impaired 
anti-tumor effect in vivo [44]. Thus, it is expected that 
decreasing the treatment dose of cyclophosphamide 
with co-administration of o-PDA would be beneficial 
toward increasing direct cytocidal activity to cancer 
cells while decreasing its immunosuppressive effect. 
Recent studies demonstrated that treatment of cancer 
cells such as colon with cyclophosphamide increases the 
number of colon cancer stem cells [45].
In summary, we demonstrated the efficacy of o-PDA 
as a potent growth inhibitor for tumor cells but not nor-
mal epithelial cells. There are several issues that remain 
to be addressed regarding the mechanisms of cell growth 
inhibition by o-PDA such as the presence of cell surface 
receptors for o-PDA and the mechanisms of cell growth 
inhibition. Further systematic and extensive structure-
activity relationship studies are imperative for developing 
new Ru-arene complexes that act as effective chemothera-
peutic reagents, which may prevent invasion and metasta-
sis with inhibition of multiple processes of tumor growth.
Conclusions
We demonstrated that treatment of MDA-MB-231 
cells with o-PDA inhibited growth factor productions 
such as VEGF-A, PDGF-AA, and GM-CSF. o-PDA and 
cyclophosphamide synergistically inhibited growth of 
MDA-MB-231 cells. These results suggest that Ru-arene 
complexes are promising anti-cancer reagents by inhibit-
ing multiple processes of tumor cell growth.
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Additional files
Additional file 1: Figure S1. Inhibition of cell growth by Ru‑arene 
complexes. Various cells including HCC38 (breast cancer), HCC1806 (breast 
cancer), SK‑Br3 (breast cancer), MCF‑7 (breast cancer), SUM149 (breast 
cancer), Raji (B‑cell lymphoma), HT1080 (osteosarcoma), and Bowes (mela‑
noma) cells (2 × 105 cells/well) were incubated in the presence of o‑PDA 
() or o‑BQDI (), at various concentrations for 2 days. Dashed line represents 
the growth inhibition by incubating with Puromycin (25 mM). Cell growth 
was evaluated by colorimetric assays using WST‑1 as an indicator. Experi‑
ments were repeated three times. Results were demonstrated as a mean 
% of inhibition compared to control mean ± standard deviation (SD). 
OD450 of control cells was 0.4 to 0.5 in each cell line. *p < 0.001 (calculated 
by Student’s two‑tailed t‑test).
Additional file 2: Figure S2. Growth inhibition of MDA‑MB‑231 and 
MCF‑10A cells by Ru‑arene complexes. (A) MDA‑MB‑231 cells (2 X 105 
cells/well) were incubated in the presence of o‑PDA or o‑BQDI (A) or 
cisplatin (B) at various concentrations for 2 days. MCF‑10A cells (2 X 105 
cells/well) were incubated in the presence of o‑PDA, or o‑BQDI at various 
concentrations (C) or cisplatin (D) for 2 days. Cell growth was evaluated 
by colorimetric assays using WST‑1 as an indicator. Symbols: o‑PDA (), 
o‑BQDI (). Dashed line represents the growth inhibition by incubating 
with Puromycin (25 mM). Experiments were repeated three times. Results 
were demonstrated as a mean  % of inhibition compared to control 
mean ± standard deviation (SD). OD450 of control cells was 0.4 to 0.5 in 
each cell line. *p < 0.001 (calculated by Student’s two‑tailed t‑test).
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